RFC
CPRX

Regions Financial Corp’s Catalyst Pharmaceutical CPRX Stock Holding History

Regions Financial Corp’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,000
Closed -$5K – 997
2019
Q1 		$5K Buy
+1,000
New +$2.94K ﹤0.01% 1658

Other funds holding CPRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Regions Financial Corp's CPRX Position: Q2 2019 in Review

Regions Financial Corp sold out of Catalyst Pharmaceutical (CPRX) in Q2 2019, closing a stake of 1,000 shares — an estimated $5K sold.

Regions Financial Corp first reported a position in CPRX in Q1 2019 and held it in 1 quarter. The position peaked at $5K in Q1 2019. 101 funds tracked by Wall St. Rank hold CPRX as of Q2 2019.

  • Regions Financial Corp reported no remaining Catalyst Pharmaceutical position as of Q2 2019 after selling out during the quarter.
  • Regions Financial Corp sold 1,000 Catalyst Pharmaceutical shares in Q2 2019, an estimated $5K.
  • Regions Financial Corp first reported a position in Catalyst Pharmaceutical in Q1 2019 and held it in 1 quarter.
  • Regions Financial Corp's Catalyst Pharmaceutical position peaked at $5K in Q1 2019.
  • 101 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2019.

Based on Regions Financial Corp's 13F filing for Q2 2019, filed 19 Jul 2019.